Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-05T17:03:53.217Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety of concomitant tranylcypromine treatment during electroconvulsive therapy (ECT) series

Published online by Cambridge University Press:  01 September 2022

E. Kavakbasi ,
G.M. Ciftci ,
M. Tonkul  and
B. Baune
E. Kavakbasi*
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
G.M. Ciftci
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
M. Tonkul
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
B. Baune
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Tranylcypromine (TCP), an irreversible monoamine oxidase inhibitor (MAOI), is recommended for difficult-to-treat depression. Besides the requirement of a low-tyramine diet, there are concerns about the safety of TCP treatment during anaesthesia and electroconvulsive therapy (ECT). For safety reasons, many psychiatrists prefer to terminate TCP before ECT.

Objectives

To assess the safety of tranylcypromine treatment during ECT series in patients with difficult-to-treat depression (DTD).

Methods

In this retrospective study we report on n=19 patients, who were treated with tranylcypromine during the ECT series. ECT parameters, clinical and safety data were obtained from our clinical database.

Results

Mean age of patients was 51 years (range 29-77) at time of the first ECT sessions. 58 % (n=11) of patients were female. In total, 198 ECT sessions were analysed (mean 11, median 9,5 per patient). Mean TCP dose was 44 mg at time of first ECT (median 43). Concomitant TCP and ECT treatments were well tolerated during the entire ECT series. In one case TCP treatment was discontinued due to self-limiting bigeminus during the ECT session. In another case TCP and other drugs as well as the ECT series were stopped after the patient developed delirium. At the end of ECT series the mean TCP dosage was 37 mg.

Conclusions

Tranylcypromine appears to be safe during ECT series and does not necessarily have to be terminated prior to electroconvulsive therapy.

Disclosure

No significant relationships.

Keywords

Electroconvulsive therapyECTTranylcypromineMAOI
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S261
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.